Stockwatch: In earnings season, the house always wins
This article was originally published in Scrip
As the third week of the full-year 2012 financial blizzard of reports brought the main part of earnings season to a stateside snowbound close, the take-home message of a difficult financial 2013 softened by spin-offs and other transactions meant that there will always be at least one winner, even if it is not an investor.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.